These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25533629)

  • 1. Preclinical studies of the potent and selective nicotinic α4β2 receptor ligand VMY-2-95.
    Kong H; Song JK; Yenugonda VM; Zhang L; Shuo T; Cheema AK; Kong Y; Du GH; Brown ML
    Mol Pharm; 2015 Feb; 12(2):393-402. PubMed ID: 25533629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and discovery of picomolar selective α4β2 nicotinic acetylcholine receptor ligands.
    Yenugonda VM; Xiao Y; Levin ED; Rezvani AH; Tran T; Al-Muhtasib N; Sahibzada N; Xie T; Wells C; Slade S; Johnson JE; Dakshanamurthy S; Kong HS; Tomita Y; Liu Y; Paige M; Kellar KJ; Brown ML
    J Med Chem; 2013 Nov; 56(21):8404-21. PubMed ID: 24047231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
    Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
    Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential efficacies of the nicotinic α4β2 desensitizing agents in reducing nicotine self-administration in female rats.
    Rezvani AH; Slade S; Wells C; Yenugonda VM; Liu Y; Brown ML; Xiao Y; Kellar KJ; Levin ED
    Psychopharmacology (Berl); 2017 Sep; 234(17):2517-2523. PubMed ID: 28555315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics.
    Jayaraman R; Pilla Reddy V; Pasha MK; Wang H; Sangthongpitag K; Yeo P; Hu CY; Wu X; Xin L; Goh E; New LS; Ethirajulu K
    Drug Metab Dispos; 2011 Dec; 39(12):2219-32. PubMed ID: 21873472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The high-affinity nAChR partial agonists varenicline and sazetidine-A exhibit reinforcing properties in rats.
    Paterson NE; Min W; Hackett A; Lowe D; Hanania T; Caldarone B; Ghavami A
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1455-64. PubMed ID: 20708056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and nicotinic acetylcholine receptor in vivo binding properties of 2-fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine: a new positron emission tomography ligand for nicotinic receptors.
    Doll F; Dolci L; Valette H; Hinnen F; Vaufrey F; Guenther I; Fuseau C; Coulon C; Bottlaender M; Crouzel C
    J Med Chem; 1999 Jun; 42(12):2251-9. PubMed ID: 10377231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of analgesic efficacy but not side effects: co-administration of an α4β2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats.
    Zhu CZ; Chin CL; Rustay NR; Zhong C; Mikusa J; Chandran P; Salyers A; Gomez E; Simler G; Lewis LG; Gauvin D; Baker S; Pai M; Tovcimak A; Brown J; Komater V; Fox GB; Decker MW; Jacobson PB; Gopalakrishnan M; Lee CH; Honore P
    Biochem Pharmacol; 2011 Oct; 82(8):967-76. PubMed ID: 21620806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sazetidine-A is a potent and selective agonist at native and recombinant alpha 4 beta 2 nicotinic acetylcholine receptors.
    Zwart R; Carbone AL; Moroni M; Bermudez I; Mogg AJ; Folly EA; Broad LM; Williams AC; Zhang D; Ding C; Heinz BA; Sher E
    Mol Pharmacol; 2008 Jun; 73(6):1838-43. PubMed ID: 18367540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α4β2 Nicotinic receptor desensitizing compounds can decrease self-administration of cocaine and methamphetamine in rats.
    Levin ED; Rezvani AH; Wells C; Slade S; Yenugonda VM; Liu Y; Brown ML; Xiao Y; Kellar KJ
    Eur J Pharmacol; 2019 Feb; 845():1-7. PubMed ID: 30529197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration.
    Kem WR; Mahnir VM; Prokai L; Papke RL; Cao X; LeFrancois S; Wildeboer K; Prokai-Tatrai K; Porter-Papke J; Soti F
    Mol Pharmacol; 2004 Jan; 65(1):56-67. PubMed ID: 14722237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α4β2 neuronal nicotinic receptor positive allosteric modulation: an approach for improving the therapeutic index of α4β2 nAChR agonists in pain.
    Lee CH; Zhu C; Malysz J; Campbell T; Shaughnessy T; Honore P; Polakowski J; Gopalakrishnan M
    Biochem Pharmacol; 2011 Oct; 82(8):959-66. PubMed ID: 21763685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro metabolism and drug interaction potential of a new highly potent anti-cytomegalovirus molecule, CMV423 (2-chloro 3-pyridine 3-yl 5,6,7,8-tetrahydroindolizine I-carboxamide).
    Bournique B; Lambert N; Boukaiba R; Martinet M
    Br J Clin Pharmacol; 2001 Jul; 52(1):53-63. PubMed ID: 11453890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sazetidine-A, a novel ligand that desensitizes alpha4beta2 nicotinic acetylcholine receptors without activating them.
    Xiao Y; Fan H; Musachio JL; Wei ZL; Chellappan SK; Kozikowski AP; Kellar KJ
    Mol Pharmacol; 2006 Oct; 70(4):1454-60. PubMed ID: 16857741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological MRI in awake rats predicts selective binding of alpha4beta2 nicotinic receptors.
    Chin CL; Pauly JR; Surber BW; Skoubis PD; McGaraughty S; Hradil VP; Luo Y; Cox BF; Fox GB
    Synapse; 2008 Mar; 62(3):159-68. PubMed ID: 18081183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemistry and pharmacological characterization of novel nitrogen analogues of AMOP-H-OH (Sazetidine-A, 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol) as α4β2-nicotinic acetylcholine receptor-selective partial agonists.
    Liu J; Eaton JB; Caldarone B; Lukas RJ; Kozikowski AP
    J Med Chem; 2010 Oct; 53(19):6973-85. PubMed ID: 20822184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization.
    Donnelly-Roberts DL; Puttfarcken PS; Kuntzweiler TA; Briggs CA; Anderson DJ; Campbell JE; Piattoni-Kaplan M; McKenna DG; Wasicak JT; Holladay MW; Williams M; Arneric SP
    J Pharmacol Exp Ther; 1998 May; 285(2):777-86. PubMed ID: 9580626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.
    Venkatesh PR; Goh E; Zeng P; New LS; Xin L; Pasha MK; Sangthongpitag K; Yeo P; Kantharaj E
    Biol Pharm Bull; 2007 May; 30(5):1021-4. PubMed ID: 17473456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transport of active flavonoids, based on cytotoxicity and lipophilicity: an evaluation using the blood-brain barrier cell and Caco-2 cell models.
    Yang Y; Bai L; Li X; Xiong J; Xu P; Guo C; Xue M
    Toxicol In Vitro; 2014 Apr; 28(3):388-96. PubMed ID: 24362044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.